MiRACULOUS project

MiRNA-based Innovative Formulations for the Regulation and Control of Oncological Unhealing Sores

MiRACULOUS overview

The MiRACULOUS Project is a multidisciplinary collaboration aimed at transforming chronic wound care. By developing targeted, innovative therapies, the project focuses on improving healing, reducing scarring, and enhancing the quality of life for patients with chronic wounds, including those caused by oncology treatments.

Key innovations

The project integrates three groundbreaking technologies:

Therapeutic microRNA-loaded extracellular vesicles (EVs): Enhances wound healing and neoangiogenesis with targeted gene modulators.
Medical-grade atelocollagen biomaterials: Ensures sustained delivery, biocompatibility and antiscarring properties.
Natural bioactive extracts: Offers antimicrobial, anti-inflammatory and tissue regeneration benefits.

MiRACULOUS partners

This project is made possible through the expertise of the following collaborators:

Theramir Ltd: Leading the development of targeted microRNA-based therapies and EV delivery systems.

Promed Bioscience: Specializing in high-purity medical-grade atelocollagen for regenerative medicine.

RSL Revolutionary Labs: Providing advanced formulations of natural bioactive extracts tailored for wound healing applications.

Vet Ex Machina Ltd: Conducts advanced preclinical and veterinary clinical trials, including in vivo and ex vivo testing, leveraging state-of-the-art facilities and expertise in tissue engineering, medical devices, and cell-based therapies.

Funding Agency

The MiRACULOUS Project is funded by the Research and Innovation Foundation (RIF) under the RESTART 2016-2020 Programmes for Research, Technological Development, and Innovation. This initiative aligns with Cyprus’s Smart Specialization Strategy (S3Cy) in the areas of Health and Biotechnology.

Roles and Activities

Theramir Ltd (Host Organization): Oversees all project phases, ensuring alignment with objectives and milestones, coordinates commercialization efforts, builds on the EVmiR® platform expertise and supervises the in vitro and ex vivo testing of the finalised product.

Promed Bioscience: Develops and characterizes specialised atelocollagen biomaterials with key characterestics of the product design.

RSL Revolutionary Labs: Prepares tailored natural extract formulations and contributes to final product development and pilot production of the product.

Vet Ex Machina Ltd: Executes in vivo testing to validate efficacy and biocompatibility of the therapeutic formulation.

Project Goals

Accelerate wound healing and reduce complications such as scarring and infections.

Create a therapeutic solution for chronic wounds caused by oncology treatments, diabetes, and pressure ulcers.

Develop a product that combines microRNA-enriched EVs, collagen biomaterials, and natural extracts for maximum efficacy.

Impact

This groundbreaking project addresses a significant unmet need in the chronic wound care market, which is projected to reach $27.2 billion by 2027. By providing an innovative solution, MiRACULOUS aims to:

Improve clinical outcomes for patients worldwide.
Enhance the competitiveness of the participating SMEs.
Contribute to the growth of Cyprus’s biotechnology and healthcare sectors.

Stay tuned for updates as the MiRACULOUS Project sets new standards in regenerative medicine and wound care.